Jump to ContentJump to Main Navigation

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Schlattmann, Peter / Tate, Jillian R. / Tsongalis, Gregory J.

12 Issues per year


IMPACT FACTOR 2014: 2.707
Rank 6 out of 30 in category Medical Laboratory Technology in the 2014 Thomson Reuters Journal Citation Report/Science Edition

SCImago Journal Rank (SJR) 2014: 0.741
Source Normalized Impact per Paper (SNIP) 2014: 1.011
Impact per Publication (IPP) 2014: 2.310

VolumeIssuePage

Issues

Pandemic influenza A (H1N1) 2009: the experience of the first six months

Jean Maritz1 / Leana Maree1 / Wolfgang Preiser1

1Division of Medical Virology, Department of Pathology, National Health Laboratory Service and University of Stellenbosch, Cape Town, South Africa

Corresponding authors: Jean Maritz, MBChB MSc and Leana Maree, MBChB, Division of Medical Virology, Department of Pathology, National Health Laboratory Service and University of Stellenbosch, Cape Town 7505, South Africa Phone: +27 21 938 9347, Fax: +27 21 938 9361, ;

Citation Information: Clinical Chemistry and Laboratory Medicine. Volume 48, Issue 1, Pages 11–21, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: 10.1515/CCLM.2010.023, December 2009

Publication History

Received:
2009-11-21
Accepted:
2009-11-23
Published Online:
2009-12-22

Abstract

After a break of 41 years, 2009 saw the first influenza pandemic of the 21st century caused by a triple-reassortant influenza A (H1N1) virus. The current estimated case fatality rate is lower than that of previous influenza pandemics, but this may change as the pandemic evolves. Illness frequently occurs in previously healthy, young adults with a wide range of clinical presentations. The majority of circulating pandemic viruses remain susceptible to neuraminidase inhibitors, although all strains are intrinsically resistant to the adamantanes. Monovalent vaccines against the pandemic strain are available in both live attenuated and inactivated forms. This review aims to summarise important virological, epidemiological and clinical aspects of the pandemic influenza A (H1N1) virus for physicians and other clinical personnel.

Clin Chem Lab Med 2010;48:11–21.

Keywords: H1N1; influenza A virus; pandemic; review; swine flu

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Jiahong Xu, Yayuan Zheng, Mingmin Wang, Jiangmin Zhao, Qing Zhan, Mingxu Fu, Qianyi Wang, Junjie Xiao, and Yan Cheng
Medical Science Monitor, 2011, Volume 17, Number 7, Page PH60
[2]
Vidyashankara Iyer, Mangala Roshan Liyanage, Yoko Shoji, Jessica A. Chichester, R. Mark Jones, Vidadi Yusibov, Sangeeta B. Joshi, and C. Russell Middaugh
Human Vaccines & Immunotherapeutics, 2012, Volume 8, Number 4, Page 453
[3]
Clayton A. Wiley, Donald M. Carter, Ted M. Ross, and Stephanie J. Bissel
Influenza and Other Respiratory Viruses, 2012, Volume 6, Number 3, Page e1
[4]
Guillaume Lefevre, Jean-Christophe Ianotto, Adrian Tempescul, Philippe Lemoine, Gaelle Guillerm, and Christian Berthou
Annals of Hematology, 2011, Volume 90, Number 9, Page 1111
[5]
Giuseppe Lippi and Mario Plebani
Clinical Chemistry and Laboratory Medicine, 2010, Volume 48, Number 1, Page 1
[6]
Guolin Xu, Tseng-Ming Hsieh, Daniel Y. S. Lee, Emril Mohamed Ali, Hong Xie, Xing Lun Looi, Evelyn S.-C. Koay, Mo-Huang Li, and Jackie Y. Ying
Lab on a Chip, 2010, Volume 10, Number 22, Page 3103

Comments (0)

Please log in or register to comment.